Abstract
Cancer physiology can be a new significant target for therapy. Nonsurgical approaches to cancer treatment, primarily radiation therapy and chemotherapy, are almost exclusively based on agents that kill cells. The main problem with these current treatments, however, is that they do not have specificity for cancer cells. In the case of antineoplastic drugs, it is primarily the rapid proliferation of many of the cancer cells that makes them more sensitive to cell killing than their normal cellular counterparts, for radiation therapy, a degree of specificity is achieved by localizing the radiation to the tumour and its immediate surrounding normal tissue. However, both treatments are limited by their toxic effects on normal cells. To achieve greater efficacy many researchers are attempting to stress differences between normal and malignant cells at the cellular milieu and biomolecular properties. The physiology of solid tumours at the microenvironmental level is sufficiently different from that of the normal tissues from which they arise to provide a unique and selective target for cancer treatment.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Gray LH, Conger AD, Ebert M et al. Concentration of oxygen dissolved in tissue at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953; 26:638–48.
Thomlinson RH, Gray LH. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 1955; 9:539–49.
Moulder JE, Rockwell S. Tumor hypoxia: Its impact on cancer therapy. Cancer Metastasis Rev 1987; 5:313–41.
Brown JM. The hypoxic cell: A target for selective cancer therapy. Cancer Res 1999; 59:5863–70.
Rauth AM, Melo T, Misra V. Bioreductive therapies: An overview of drugs and their mechanis m of action. Int J Radiat Oncol Biol Phys 1998; 42:755–62.
Wouters BG, Wang LH, Brown JM. Tirapazamine: A new drug producing tumor specific enhancement of platinum-based chemotherapy in non small cell lung cancer. Ann Oncol 1999; 10(suppl 5):S29–S33.
Graeber TG, Osmanian C, Jacks T. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996; 379:88–91.
Lin A, Cosby L, Shansky C et al. Potential bioreductive alkylating agents. 1. Benzoquinone derivates. J Med Chem 1972; 15:1247–52.
Adams GE, Stratford IJ. Bioreductive drugs for cancer therapy: The search for tumour specificity. Int J Radiat Oncol Biol Phys 1994; 29:231–8.
Teicher BA, Holden SA, Al-Achi A et al. Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulation in vivo in the FSallC murine fibrosarcoma. Cancer Res 1990; 50:3339–44.
Binley L, Iqball S, Kingsman S et al. An adenoviral vector regulated by hypoxia for the treatment of ischaemic disease and cancer. Gene Ther 1999; 6:1721–7.
Zaffaroni N, Fiorentini G, De Giorgi U. Hyperthermia and hypoxia: New developments in anti-cancer chemotherapy. Eur J Surg Oncol 2001; 27:340–2.
Guadagni S, Fiorentini G, Palumbo G et al. Hypoxic pelvic perfusion with mitomycin C using a simplified ballon-occlusion technique in the treatment of patients with unresectable locally recurrent rectal cancer. Arch Surg 2001; 136(1):105–12.
Guadagni S, Russo F, Rossi CR et al. Deliberate hypoxic pelvic and limb chemoperfusion in the treatment of recurrent melanoma. Am J Sur 2002; 183:28–36.
Fiorentini G, Poddie D, Graziani G et al. Hypoxic isolated limb perfusion with mitomycin C in locally recurrent melanoma and sarcoma: Results of a phase II study. Reg Cancer Treat 1995; 8:135–9.
Brown JM, Giacca AJ. The unique physiology of solid tumore: Opportunities (and problems) for cancer therapy. Cancer Res 1998; 58:1408–16.
Urano M, Kuroda M, Nishimura Y. For the clinical application of thermochemotherapy given at mild temperatures. Int J Hyperther 1999; 2:79–107.
Zaffaroni N, Villa R, Daidone MG et al. Antitumor activity of hyperthermia alone or in combination with cisplatin and melphalan in primary cultures of human malignant melanoma. Int J Cell Cloning 1989; 7:385–94.
Kusumoto T, Holden SA, Ara G et al. Hyperthermia and platinum complexes: Time between treatments and synergy in vitro and in vivo. Int J Hyperther 1995; 11:575–86.
Bates DA, Mackillop WJ. Effect of hyperthermia on the uptake and cytotoxicity of melphalan in Chinese hamster ovary cells. Int J Radiat Onco/Biol Phys 1998; 16:187–91.
Zaffaroni N, Villa R, Orlandi L et al. Effect of hyperthrmia on the formation and removal of DNA interstrand cross-links induced by melphalan in primary cultures of human malignant melanoma. Int J Hyperther 1992; 8:341–9.
Orlandi L, Zaffaroni N, Bearzatto A et al. Effect of melphalan and hyperthermia on cell cycle progression and cyclin Bl expression in human melanoma cells. Cell Prolif 1995; 28:617–30.
Orlandi L, Zaffaroni N, Bearzatto A et al. Effect of melphalan and hyperthermia on p34cdc2 kinase activity in human melanoma cells. Br J Cancer 1996; 74:1924–8.
Rietbroek RC, van de Vaart PJ, Haveman J et al. Hyperthermia enhances the cytotoxic activity and platinum-DNA adduct formation of lobaplatin and oxaliplatin in cultured SW 1573 cells. J Cancer Res Clin Oncol 1997; 123:6–12.
Orlandi L, Costa A, Zaffaroni N et al. Relevance of cell kinetic and ploidy characteristics for the thermal response of malignant melanoma primary cultures. Int J Oncol 1993; 2:523–6.
Richards EH, Hickman JA, Masters JR. Heat shock protein expression in testis and bladder cancer celi lines exhibiting differential sensitivity to heat. Br J Cancer 1995; 72:620–6.
Takemoto M, Kuroda M, Urano M et al. Effect of various chemotherapeutic agents given with mild hyperthermia on different types of tumours. Int J Hyperthermia 2003; 19(2):193–203.
Urano M, Ling CC. Thermal enhancement of melphalan and oxaliplatin cytotoxicity in vitro. Int J Hyperthermia 2002; 18(4):307–15.
Mohamed F, Stuart OA, Glehen O et al. Docetaxel and hyperthermia: Factors that modify thermal enhancement. J Surg Oncol 2004; 88(1):14–20.
Li GC, He F, Shao X et al. Adenovirus-mediated heat-activated antisense Ku70 expression radiosensitizes tumor cells in vitro and in vivo. Cancer Res 2003; 63(12):3268–74.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2006 Landes Bioscience and Springer Science+Business Media
About this chapter
Cite this chapter
Fiorentini, G., De Giorgi, U., Cantore, M., Mambrini, A., Guadagni, S. (2006). A Step Deep on Hyperthermia, Hypoxia and Chemotherapy Interactions. In: Hyperthermia in Cancer Treatment: A Primer. Medical Intelligence Unit. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-33441-7_11
Download citation
DOI: https://doi.org/10.1007/978-0-387-33441-7_11
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-33440-0
Online ISBN: 978-0-387-33441-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)